Coadministration of the selective COX-2 inhibitor SC236 significantly aggravated doxorubicin-induced cardiac injury in rats, increasing plasma lactate dehydrogenase from 578 U/l to 1,552 U/l.
Does inhibition of COX-2 aggravate doxorubicin-mediated cardiac injury in vivo?
Inhibition of COX-2 aggravates doxorubicin-induced cardiotoxicity in vivo, suggesting that COX-2 induction is a compensatory protective mechanism mediated by prostacyclin.
Absolute Event Rate: 1552% vs 578%
p-value: p=0.02
chemicals were obtained from Sigma Chemical Co.(St.
Dowd et al. (2001) studied Doxorubicin-induced cardiac injury. SC236 (COX-2 inhibitor) with Doxorubicin vs. Doxorubicin alone was evaluated on Plasma lactate dehydrogenase (LDH) level at 4 hours (p=0.02). Coadministration of the selective COX-2 inhibitor SC236 significantly aggravated doxorubicin-induced cardiac injury in rats, increasing plasma lactate dehydrogenase from 578 U/l to 1,552 U/l.